Published in Can J Gastroenterol on February 01, 2010
Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther (2011) 1.52
Inflammatory bowel disease as a model for translating the microbiome. Immunity (2014) 1.39
Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials (2013) 0.97
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.92
Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology (2014) 0.92
Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids Surf B Biointerfaces (2015) 0.78
Moxibustion combined with acupuncture increases tight junction protein expression in Crohn's disease patients. World J Gastroenterol (2015) 0.78
Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol (2015) 0.78
ZnO nanoparticles act as supportive therapy in DSS-induced ulcerative colitis in mice by maintaining gut homeostasis and activating Nrf2 signaling. Sci Rep (2017) 0.78
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther (2017) 0.76
Inflammatory bowel disease: A descriptive study of 716 local Chilean patients. World J Gastroenterol (2016) 0.75
Herb-partitioned moxibustion upregulated the expression of colonic epithelial tight junction-related proteins in Crohn's disease model rats. Chin Med (2016) 0.75
Brassica-Derived Plant Bioactives as Modulators of Chemopreventive and Inflammatory Signaling Pathways. Int J Mol Sci (2017) 0.75
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med (2003) 2.73
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther (1972) 2.37
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Management of Crohn's disease in adults. Am J Gastroenterol (2001) 2.09
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med (2005) 2.06
Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut (2004) 1.85
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut (2008) 1.75
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2007) 1.72
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut (1998) 1.58
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2003) 1.57
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol (2003) 1.56
Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther (2008) 1.41
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol (1996) 1.41
Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem (1999) 1.38
Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology (1999) 1.35
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 1.29
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol (2007) 1.28
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2006) 1.24
Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest (1982) 1.20
Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci (2006) 1.19
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis (2009) 1.15
Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther (2006) 1.14
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2003) 1.13
Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology (1990) 1.09
Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig (2005) 0.98
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol (2000) 0.97
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis (2001) 0.96
The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol (2003) 0.94
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther (1995) 0.89
Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut (1992) 0.87
Molecular underpinnings of cancer in ulcerative colitis. Curr Opin Gastroenterol (2003) 0.87
Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs (2007) 0.82
Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol (1998) 0.81
Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther (2002) 0.79
The treatment of the rheumatological manifestations of the inflammatory bowel diseases. Rheumatol Int (2006) 0.78
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis (2007) 0.77
Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol (2007) 0.77
Multi-matrix system mesalamine: to use or not to use. Ann Pharmacother (2008) 0.76
Managing the risks of IBD therapy. Curr Gastroenterol Rep (2009) 0.79